Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab, Cabiralizumab, and SBRT for Pancreatic Cancer
NCT03599362Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cabiralizumab in pancreatic cancer (PC), sponsored by NYU Langone Health. Started Jul 2018; status: terminated.
02
Drugs
cabiralizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT03599362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03599362.